Research

February 13, 2018 | Categories: News, Research

New Research Grant Recipient Announced

January 11, 2018 | Categories: News, Research

In 2016, the Melanoma Research Foundation Breakthrough Consortium (MRFBC) convened a meeting of its scientific advisors to assess the greatest areas of need in the current research landscape to guide its grant funding. Following a thorough examination, the assembled researchers arrived at a consensus recommendation to encourage a critical mass of innovative young researchers to enter the promising field of melanoma immunotherapy.

January 2, 2018 | Categories: News, Research, Treatment

Congress Must Protect DoD Medical Research Funding

September 26, 2017 | Categories: News, Policy, Research

Since 1992, the Department of Defense Congressionally-Directed Medical Research Program (CDMRP) has transformed healthcare for service members and the American public through innovative and impactful biomedical research. As of 2017, Congress has, on a bipartisan basis, provided the CDMRP with $11.9 billion in funding to support high impact, high risk, and high gain projects that other agencies and private investors may be unwilling to fund.

Apply for the Medical Student Research Award

September 1, 2017 | Categories: News, Research

The Melanoma Reserach Foundation (MRF) is now accepting applications for the 2018 Medical Student Research Award. The MRF has been awarding this research grant since 2011 and in this time 35 grants have been awarded to students at 24 different institutions. The purpose of the Medical Student Research Award is to promote scientific inquiry and research opportunities to medical students early in their careers by funding concise clinical or laboratory-based research projects focused on better understanding the prevention, biology, and treatment of melanoma.

What's Next: 

FDA Expands Approval of Ipilimumab For Pediatric Melanoma Patients

August 3, 2017 | Categories: News, Research, Treatment

Last week the United States Food and Drug Administration (FDA) expanded approval of Yervoy (ipilimumab) to include pediatric patients ages 12 years and older with unresectable or metastatic melanoma. Yervoy, a monoclonal antibody that activates the immune system by blocking the CTLA-4 receptor, was first approved in 2011 to treat unresectable or metastatic melanoma in adults.

Take Action: Stop the NIH Budget Cuts

March 21, 2017 | Categories: News, Policy, Research

The newly proposed federal budget would cut $5.8 billion from the National Institutes of Health (NIH) budget in fiscal year (FY) 2018, which would be a crippling blow to the scientific community.

In Kristin's Words: A Patient Perspective on Research

September 20, 2016 | Categories: News, Ocular Melanoma, Patient Stories, Research

Ocular melanoma patient and advocate Kristin Nocco recently participated in a first-of-its-kind patient review process to determine the recipient of OM research funding.

Summer's Story: The Need for an OM Patient Registry

August 24, 2016 | Categories: Causes, Ocular Melanoma, Patient Stories, Research

Summer shares her ocular melanoma story and why she joined the #CUREOM Unite! campaign to support the development of a national ocular melanoma patient registry.

Children and Melanoma

January 30, 2013 | Categories: Research

Years ago I worked at a hospital for children, raising money for pediatric medical research. The importance of this work was evident every time I walked the halls of the hospital. Seeing young children transported in little red wagons outfitted with IV poles was a powerful motivation to work harder for better therapies and cures.

Pages